Comparison of clinical efficacy between surgical re-resection and radiofrequency ablation for recurrent hepatocellular carcinoma: a Meta-analysis

doi:10.3877/cma.j.issn.2095-3232.2017.01.008

Abstract

Abstract:

Objective

To compare the difference of clinical efficacy between surgical re-resection (SRR) and radiofrequency ablation (RFA) for recurrent hepatocellular carcinoma (HCC).

Methods

Literature from the databases Medline, PubMed, Cochrane, CNKI, CBM, Wangfang and VIP between January 2010 and January 2016 was searched. The English keywords were hepatocellular carcinoma, hepatic carcinoma, liver cancer, liver neoplasms, HCC, recurrent, recurrence, relapse, recurring, resection, hepatectomy, radio frequency ablation, ablation, radio frequency, radio-frequency, RFA and PRFA. And the Chinese keywords were liver cancer, hepatocellular carcinoma, liver neoplasms, recurrence, surgery and RFA. The patients were divided into the SRR group and RFA group. The outcome indicators including the 3-year survival rate, 3-year tumor-free survival rate, 3-year recurrence rate, incidence of complications and length of hospital stay after surgery of two groups were analyzed using Meta-analysis.

Results

A total of 8 literatures, 856 patients were included in this study, including 1 randomized controlled trial and 7 retrospective studies. The Meta-analysis results revealed that no significant difference was observed in the 3-year survival rate between two groups (OR=1.02, 95%CI: 0.75-1.39, P>0.05). The 3-year tumor-free survival rate in the SSR group was significantly higher than that in the RFA group (OR=1.63, 95%CI: 1.05-2.54, P<0.05). No significant difference was observed in the 3-year recurrence rate between two groups (OR=0.85, 95%CI: 0.48-1.49, P>0.05). The incidence of complications above Clavien grade Ⅱ after surgery in the SRR group was significantly higher than that in the RFA group (OR=13.33, 95%CI: 2.43-73.06, P<0.05). The length of hospital stay in the SRR group was significantly longer than that in the RFA group (SMD=5.23, 95%CI: 2.85-7.61, P<0.05).

Conclusions

For the treatment of recurrent HCC, there is no significant difference in the overall survival rate between SRR and RFA, but the tumor-free survival rate in the SRR group is significantly higher than that in the RFA group, whereas RFA has the advantages of higher safety and shorter length of hospital stay.

Key words: Carcinoma, hepatocellular, Reoperation, Catheter ablation, Meta-analysis

Xi Chen, Peng Liu, Xianbin Zhang, Yumei Yan, Peng Gong. Comparison of clinical efficacy between surgical re-resection and radiofrequency ablation for recurrent hepatocellular carcinoma: a Meta-analysis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(01): 34-39.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2017.01.008

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2017/V06/I01/34

Figures/Tables 6

References 28

[1]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[2]	Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2013, 53(3):1020-1022.
[3]	Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer≤2 cm: results from two Western centers[J]. Hepatology, 2013, 57(4):1426-1435.
[4]	Cheung TT, Poon RT, Yuen WK, et al. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience[J]. Ann Surg, 2013, 257(3):506-511.
[5]	Shrager B, Jibara G, Schwartz M, et al. Resection of hepatocellular carcinoma without cirrhosis[J]. Ann Surg, 2012, 255(6):1135-1143.
[6]	N'Kontchou G, Mahamoudi A, Aout M. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis[J]. Hepatology, 2009, 50(5):1475-1483.
[7]	Chu KK, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population[J]. World J Hepatol, 2015, 7(11):1562-1571.
[8]	罗嘉，吴飞跃，汤明．复发性小肝癌再次手术和消融栓塞治疗的探讨[J]．中国普通外科杂志，2011, 20(7): 676-679.
[9]	董晓刚，卓越，李海军，等．复发性小肝癌再次手术与射频消融的临床分析[J]．兵团医学，2011, 30(4): 7-9.
[10]	梁惠宏，彭振维，陈敏山，等．经皮射频消融与再手术治疗单个直径≤3cm的复发性肝癌的疗效比较[J]．中华消化外科杂志，2011, 10(1): 36-39.
[11]	张辉，徐新保，何晓军，等．原发性肝癌术后复发再手术切除与射频消融治疗的疗效比较[J]．西部医学，2013, 25(12): 1816-1818.
[12]	黄新辉，黄尧，林科灿，等．复发性小肝细胞癌射频消融与再手术切除疗效的分析[J]．腹部外科，2013, 26(2): 93-95.
[13]	吴斌．原发性肝癌复发射频消融与手术治疗疗效分析[J]．中国处方药，2014, 12(11): 104, 122.
[14]	张婷婷，李开艳，罗鸿昌，等．经皮微波消融和二次手术治疗晚期复发型小肝癌的长期疗效观察[J]．中华医学杂志，2014, 94(33): 2570-2572.
[15]	Song KD, Lim HK, Rhim H, et al. Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study[J]. Radiology, 2015, 275(2): 599-608.
[16]	Troisi RI, Patriti A, Montalti R, et al. Robot assistance in liver surgery: a real advantage over a fully laparoscopic approach? results of a comparative bi-institutional analysis[J]. Int J Med Robot, 2013, 9(2):160-166.
[17]	Lai EC, Tang CN, Yang GP, et al. Multimodality laparoscopic liver resection for hepatic malignancy--from conventional total laparoscopic approach to robot-assisted laparoscopic approach[J]. Int J Surg, 2011, 9(4):324-328.
[18]	Ji WB, Wang HG, Zhao ZM, et al. Robotic-assisted laparoscopic anatomic hepatectomy in China: initial experience[J]. Ann Surg, 2011, 253(2):342-348.
[19]	Chan AC, Poon RT, Cheung TT, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma[J]. World J Surg, 2012, 36(1):151-156.
[20]	王峰杰，陈焕伟，甄作均，等．腹腔镜射频消融术在治疗复杂肝细胞癌中的应用[J/CD]．中华肝脏外科手术学电子杂志，2016, 5(5): 304-307.
[21]	孙文兵，丁雪梅，高君，等．提升肝细胞癌射频消融疗效的技术性措施：外科视角[J]．中华肝胆外科杂志，2011, 17(7): 534-538.
[22]	Yang B, Zou J, Xia J, et al. Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation[J]. Eur J Radiol, 2011, 79(2):196-200.
[23]	Yamashita S, Aoki T, Inoue Y, et al. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy[J]. Surgery, 2015, 157(3):463-472.
[24]	Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors[J]. World J Surg, 2015, 39(5):1150-1160.
[25]	Ng KK, Lo CM, Liu CL, et al. Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant[J]. Arch Surg, 2008, 143(1):68-74.
[26]	许继凡，戴珏，郭涛，等．再次肝切除治疗复发性肝癌疗效及预后因素分析[J]．中国普通外科杂志，2014, 23(7):873-877.
[27]	孙鋆泽，陆华虎，吕凌，等．影响肝癌术后复发危险因素的研究进展[J/CD]．中华临床医师杂志(电子版)，2011, 5(11):3245-3249.
[28]	Mundeleer L, Wikler D, Leloup T, et al. Development of a computer assisted system aimed at RFA liver surgery[J]. Comput Med Imaging Graph, 2008, 32(7):611-621.

作者	年份	例数	平均年龄（岁）	性别比（男∶女）		肿瘤直径（cm）
作者	年份	例数	平均年龄（岁）	SRR	RFA	SRR	RFA
罗嘉等^[8]	2011	47	-	21∶3	021∶2	-	-
董晓刚等^[9]	2011	63	52	16∶2	012∶5	-	-
梁惠宏等^[10]	2011	151	63	65∶7	069∶10	2.16±0.10	2.46±0.10
张辉等^[11]	2013	168	-	-	-	3.50	2.10
黄新辉等^[12]	2013	112	52	51∶15	036∶10	2.90±1.10	2.60±0.90
吴斌等^[13]	2014	60	60±6	38∶22	-	4.30±0.82	-
张婷婷等^[14]	2014	66	50±13	25∶2	037∶2	3.20±1.00	2.70±1.10
Song等^[15]	2015	217	55	31∶8	145∶33	2.20±1.10	1.70±0.60

作者	年份	例数	平均年龄（岁）	性别比（男∶女）		肿瘤直径（cm）
作者	年份	例数	平均年龄（岁）	SRR	RFA	SRR	RFA
罗嘉等^[8]	2011	47	-	21∶3	021∶2	-	-
董晓刚等^[9]	2011	63	52	16∶2	012∶5	-	-
梁惠宏等^[10]	2011	151	63	65∶7	069∶10	2.16±0.10	2.46±0.10
张辉等^[11]	2013	168	-	-	-	3.50	2.10
黄新辉等^[12]	2013	112	52	51∶15	036∶10	2.90±1.10	2.60±0.90
吴斌等^[13]	2014	60	60±6	38∶22	-	4.30±0.82	-
张婷婷等^[14]	2014	66	50±13	25∶2	037∶2	3.20±1.00	2.70±1.10
Song等^[15]	2015	217	55	31∶8	145∶33	2.20±1.10	1.70±0.60

Please choose a citation manager

Content to export